4kodiak / Getty Images

Drug companies are always trying to screw us with drug pricing: just look at that asshole Martin Shkreli and his 736 percent increase in drug prices.

But this week, Oregon's legislature passed a law that will make it easier to note pharmaceutical price-gouging. Governor Kate Brown signed into law the Prescription Drug Transparency Act, which requires drug manufacturers to report whenever "there was a net increase of 10 percent or more in the price of the prescription drug" over the previous year. They're also required to divulge factors related to the price increase, the costs incurred by the manufacturer to make the drug, the 25 most expensive prescription drugs produced by the manufacturer, which prescription prices have increased the most, and how those costs effect insurance premiums.

“Every Oregonian should be able to access the medications and treatments that allow them to live healthy, productive lives,” Governor Kate Brown said in a press release. “This bill brings greater transparency around drug pricing, an important step towards making life-saving and essential drugs more available and affordable.”

Oregon State Rep. Rob Nosse sponsored the bill. “This legislation will help us take the first step, a step we need to take to begin to get at the fastest growing expense we have in health care—prescription drug costs,” Nosse said in a press release from his office. “Oregonians deserve to have transparency in something as vital to good health as prescription drugs. My hope is that this legislation will set us down a path to making health care more affordable for everyone.”

Manufacturers are also subject to civil penalty if they fail to follow through on the required reports, and the bill establishes a task force to deal with the fair pricing of prescription drugs. According to the bill, "The task force shall develop a strategy to create transparency for drug prices across the entire supply chain of pharmaceutical products, including but not limited to manufacturers, insurers, pharmacy benefit managers, distributors, wholesalers and retail pharmacies."

That said, transparency is only useful when it leads to action—and for all that this new law does to force disclosure of drug prices' drastic increases, there currently isn't a system set up to dissuade pharmaceutical companies from increasing prices, nor to ensure there are repercussions of them doing so. Maybe that's something this new task force can help make happen.